Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Feb. 28, 2023	Feb. 28, 2022
Cash flows from operating activities:
Net loss	$ (30,975)	$ (20,281)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	23,316	21,682
Non-cash lease expense	1,883	1,822
Stock based compensation	8,177	7,789
Change in fair value of contingent consideration	2,084	1,005
Gain on contingent consideration for IPR&D Write-off	(1,752)	(3,121)
Change in accounts receivable allowances	560	(66)
Fixed and intangible asset impairments and disposals	144	245
Other	(317)	(27)
Changes in operating assets and liabilities:
Accounts receivable	759	(6,441)
Inventories	(12,254)	588
Prepaid expenses and other	(392)	(7,147)
Accounts payable, accrued and other liabilities	(7,109)	(11,802)
Net cash used in operating activities	(15,876)	(15,754)
Cash flows from investing activities:
Additions to property, plant and equipment	(2,756)	(3,258)
Additions to placement and evaluation units	(4,922)	(8,676)
Cash paid for acquisitions	(540)	(3,600)
Net cash used in investing activities	(8,218)	(15,534)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt	70,000	5,000
Repayment of long-term debt	(45,000)	0
Deferred financing costs on long-term debt	(751)	0
Proceeds from exercise of stock options and employee stock purchase plan	1,171	2,354
Net cash provided by financing activities	25,420	7,354
Effect of exchange rate changes on cash and cash equivalents	(40)	(337)
Increase (decrease) in cash and cash equivalents	1,286	(24,271)
Cash and cash equivalents at beginning of period	28,825	48,161
Cash and cash equivalents at end of period	30,111	23,890
Supplemental disclosure of non-cash investing and financing activities:
Accrual for capital expenditures incurred during the period	$ 140	$ (5)